PJ Online | News: New antifungal launched
The Pharmaceutical Journal
New antifungal launched
Caspofungin, the first agent in a new class of antifungals known as echinocandins, was launched this week by Merck Sharp & Dohme (see p95). Caspofungin is indicated for the treatment of invasive aspergillosis in adult patients who are intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole or whose infection has progressed or failed to improve after a minimum of seven days of prior antifungal therapy. The company says that caspofungin works by inhibiting the synthesis of a component of the fungal cell wall, beta (1,3)-D-glucan, which is not present in mammalian cells.
Citation: The Pharmaceutical Journal URI: 20007301
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now